Older Medical PatientsZOOM-INNCT07672132
Zinc Supplementation and Inflammation in Older Medical Patients
A study testing Zinc Supplement in people with Older Medical Patients, run by Herlev Hospital at 1 site in Denmark.
Trial summary
The hypothesis is that a daily supplement of 22 mg of zinc over 12 months can reduce in-flammatory biomarkers in acutely hospitalized older adults aged ≥ 65 years. The aims are to determine, in acutely hospitalized older adults aged ≥ 65 years, if a daily supplement of 22 mg of zinc over 12 months compared to control… Read more about this study
- Who is it for?
- Ages 65 years and older
- Conditions the study is for
- Older Medical Patients
- What is being tested?
- Zinc Supplement
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 220 participants
- Where
- 1 siteDenmark
- Study dates
- 2 Jun 2026to 31 May 2028
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 65 years and older
- All sexes
- No healthy volunteers
- Older adult
Who may be able to join
- above 65 years old included in ZOOM out ( clinical trials no: NCT07367412)
- admittet at the medical emergency department Herlev Hospital
Who cannot join
- Patients receiving zinc supplements (>10 mg daily) at time of inclusion
- Patients with terminal illness (life expectancy < 6 months, estimated by Clinical Frailty Scale ≥8)
- Patients receiving parenteral nutrition (partial or complete)
- Patients treated with hemodialysis or peritoneal dialysis
- Patients known with severe dementia
- Patients who do not understand Danish and patients with temporary civil person registration numbers (CPR)
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Denmark1 site, 1 recruiting
- Recruiting
Herlev Hospital
Herlev, Region Hovedstad, 2730
Emilie Zimsen, MD, +4538681616, emilie.caroline.zimsen@regionh.dk
Pernille Ellegaard, MD, +4538681616, pernille.holm.ellegaard.01@regionh.dk
About this study
Official title: ZOOM IN Study: Micronutrient Deficiencies and Effect of Zinc Supplementation on Inflammation and Occurrence of Infections in Older Medical Patients (ZOOM) - A Sub-study of a Cluster Randomized Trial
The hypothesis is that a daily supplement of 22 mg of zinc over 12 months can reduce in-flammatory biomarkers in acutely hospitalized older adults aged ≥ 65 years.
The aims are to determine, in acutely hospitalized older adults aged ≥ 65 years, if a daily supplement of 22 mg of zinc over 12 months compared to control can decrease inflammato-ry biomarkers, reduce symptoms of self-reported infection, reduce readmission and mortali-ty, increase QoL, increase physical performance, investigate potential adverse events to zinc supplement, and the changes in inflammatory biomarkers. It will also be studied if albumin-corrected zinc in plasma is a more accurate method for assessing zinc status than ordinary plasma zinc.
- Conditions
- Older Medical Patients
- Being tested
- Zinc Supplement
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Zinc SupplementDietary supplement
22 mg Zinc supplementation daily for 12 months
| Study group | Role | What they receive |
|---|---|---|
| Controlgroup | No intervention | Standard treatment |
| Intervention | Active comparator | 22 mg zinc supplementation daily for 12 months Receives: Dietary Supplement: Zinc Supplement |
What is being measured
The primary outcome is the main question the study is designed to answer.
inflammation 6 months
To evaluate the difference between the groups in plasma concentrations of IL-6 during the first 6-months. Endpoints: Plasma concentration of IL-6 (pg/ml) from baseline to 6 months
Measured: 6 months
Secondary outcomes (11)
Blood samples indicating metabolic status and risk factors
Between group difference in change in triglycerids (mmol/L)
Measured: 3 month, 6 month, 12 month
Blood samples indicating metabolic status and risk factors
Between group difference in change in cholesterol (mmol/L)
Measured: 3 month, 6 month, 12 month
Blood samples indicating metabolic status and risk factors
Between group difference in change in HbA1c (mmol/mol)
Measured: 3 month, 6 month, 12 month
Blood samples indicating metabolic status and risk factors
Between group difference in change in albumin corrected zinc (μmol/L).
Measured: 3 month, 6 month, 12 month
Patient reported Outcomes
Between group difference in change in Quality of life measured with EQ5D, and selfreported infections assessed with a homemaid, not validated questionnare.
Measured: 3,6, and 12 months
Bodycomposition
between group difference in change in fat mass (kg) and muscle mass (kg) assessed with Bioimpedance analysis- BIA meassured at Baseline and after 3, 6 and 12 months
Measured: 3, 6, and 12 months
Physical performance
between group difference in change in chair stand test 30second
Measured: 3,6, and 12 month
Physical performance
between group difference in change in handgrip strength (kg)
Measured: 3,6, and 12 month
Nutrition and zinc intake
estimating zinc intake using 24 hour recall assessment of nutritional intake. Assessing nutritional status with the Patient Generated Subjective Global Assessment (PG-SGA)
Measured: 3,6, and 12 months
Inflammation changes at 12 months
Between group difference in change in IL6 (pg/ml), IL8 (pg/ml), YKL-40 (pg/ml)
(IL6 at 6 months are primary outcomes)
Measured: 3, 6, and 12 months
Methods for assessing zinc: Free zinc binding capacity(μmol/L) vs. plasma zinc(μmol/L) (with and without adjustments for albumin)
Evaluating the best way to assess zinc status in humans, and the association to occurring infections and readmissions
Measured: 3, 6, and 12 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted26 Jun 2026
- Study start2 Jun 2026
- Primary completion31 May 2027 (estimated)
- Study completion31 May 2028 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Older Medical PatientsStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 220 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Herlev Hospital
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Cecilia Margareta Lund, Herlev Hospital
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07672132
- Sponsor's protocol ID
- ZOOM-IN
- Acronym
- ZOOM-IN
- Status last verified
- Jun 2026
- First submitted
- 28 May 2026
- Last updated
- 24 Sep 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 24 Sep 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- ZOOM IN Study: Micronutrient Deficiencies and Effect of Zinc Supplementation on Inflammation and Occurrence of Infections in Older Medical Patients (ZOOM) - A Sub-study of a Cluster Randomized Trial
- ClinicalTrials.gov ID
- NCT07672132
- Acronym / sponsor ID
- ZOOM-IN / ZOOM-IN
- Conditions
- Older Medical Patients
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 220 participants (estimated)
- Lead sponsor
- Herlev HospitalUniversity, hospital or other
- Study start
- 2 Jun 2026 (actual)
- Primary completion
- 31 May 2027 (estimated)
- Study completion
- 31 May 2028 (estimated)
- First posted
- 26 Jun 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The hypothesis is that a daily supplement of 22 mg of zinc over 12 months can reduce in-flammatory biomarkers in acutely hospitalized older adults aged ≥ 65 years.
The aims are to determine, in acutely hospitalized older adults aged ≥ 65 years, if a daily supplement of 22 mg of zinc over 12 months compared to control can decrease inflammato-ry biomarkers, reduce symptoms of self-reported infection, reduce readmission and mortali-ty, increase QoL, increase physical performance, investigate potential adverse events to zinc supplement, and the changes in inflammatory biomarkers. It will also be studied if albumin-corrected zinc in plasma is a more accurate method for assessing zinc status than ordinary plasma zinc.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Controlgroup | No intervention | –Standard treatment |
| Intervention | Active comparator | Dietary Supplement: Zinc Supplement22 mg zinc supplementation daily for 12 months |
Who may qualify
- Ages
- 65 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Older adult
Key inclusion criteria (2 listed)
- above 65 years old included in ZOOM out ( clinical trials no: NCT07367412)
- admittet at the medical emergency department Herlev Hospital
Key exclusion criteria (6 listed)
- Patients receiving zinc supplements (>10 mg daily) at time of inclusion
- Patients with terminal illness (life expectancy < 6 months, estimated by Clinical Frailty Scale ≥8)
- Patients receiving parenteral nutrition (partial or complete)
- Patients treated with hemodialysis or peritoneal dialysis
- Patients known with severe dementia
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Zinc Supplement22 mg Zinc supplementation daily for 12 months | Dietary supplement | Intervention |
Primary outcome
inflammation 6 months
Time frame: 6 months
To evaluate the difference between the groups in plasma concentrations of IL-6 during the first 6-months. Endpoints: Plasma concentration of IL-6 (pg/ml) from baseline to 6 months
11 secondary outcomes
Blood samples indicating metabolic status and risk factors
Time frame: 3 month, 6 month, 12 month
Blood samples indicating metabolic status and risk factors
Time frame: 3 month, 6 month, 12 month
Blood samples indicating metabolic status and risk factors
Time frame: 3 month, 6 month, 12 month
Blood samples indicating metabolic status and risk factors
Time frame: 3 month, 6 month, 12 month
Patient reported Outcomes
Time frame: 3,6, and 12 months
Bodycomposition
Time frame: 3, 6, and 12 months
Physical performance
Time frame: 3,6, and 12 month
Physical performance
Time frame: 3,6, and 12 month
Nutrition and zinc intake
Time frame: 3,6, and 12 months
Inflammation changes at 12 months
Time frame: 3, 6, and 12 months
Methods for assessing zinc: Free zinc binding capacity(μmol/L) vs. plasma zinc(μmol/L) (with and without adjustments for albumin)
Time frame: 3, 6, and 12 months
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 24 Sep 2026.
- Individual participant dataSharing planned: No
Related trials for Older Medical Patients
Enrolling by invitationObservational study
An Observational Post-Authorization Safety and Effectiveness Study of Ravulizumab in Adult Patients Aged 18 and Older Diagnosed With Paroxysmal Nocturnal Hemoglobinuria Using Multicenter Electronic Medical Records in South Korea
Hemoglobinuria, Paroxysmal
Enrolling by invitation
N-of-1 Trial to Promote Beta-Blocker Titration in Heart Failure
Heart Failure, Beta-blocker
Not yet recruiting
Evaluation of a Hospital Program to Prevent Postoperative Delirium in Older Patients
Postoperative Delirium, Delirium Prevention
RecruitingObservational study
PIM Incidence in Older Cardiovascular Patients During COVID-19 Pandemics
Potentially Inappropriate Medications
Recruiting
Zinc Supplementation and Infections in Older Medical Patients
Older Adults (65 Years and Older), Medical Patients in the Emergency Department
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Zinc Supplement in people with Older Medical Patients, run by Herlev Hospital at 1 site in Denmark.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 6 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 24 Sep 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Denmark. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Cecilia M Lund, MD, PhD (+4538686112, cecilia.margareta.lund.01@regionh.dk), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
inflammation 6 months (time frame: 6 months). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 24 Sep 2026.